CINCINNATI--(BUSINESS WIRE)--Feb. 26, 2019--
Aerpio Pharmaceuticals, Inc. (NASDAQ:ARPO), a biopharmaceutical company
focused on developing compounds that activate Tie2 to treat ocular
diseases and diabetic complications, today announced that its fourth
quarter and full year 2018 financial results will be released before the
market opens on Tuesday, March 5, 2019. Following the release, the
Company will host a live conference call and webcast at 8:30 a.m. EST to
discuss the Company’s financial results and provide a general business
The live webcast and a replay may be accessed by visiting Aerpio's
website at http://ir.aerpio.com/.
Please connect to the Company's website at least 15 minutes prior to the
live webcast to ensure adequate time for any software download that may
be needed to access the webcast. Alternatively, please call (877)
216-7943 (U.S.) or (417) 629-5045 (international) to listen to the live
conference call. The conference ID number for the live call is 4778807.
Please dial in approximately 10 minutes prior to the call. Telephone
replay will be available approximately two hours after the call. To
access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406
(international). The conference ID number for the replay is 4778807.
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on
advancing first-in-class compounds that activate Tie2 to treat ocular
diseases and complications of diabetes. The Company’s lead compound,
AKB-9778, is a systemically-administered small molecule activator of the
Tie2 pathway (via highly selective and potent deactivation of VE-PTP)
and is in clinical development for the treatment of non-proliferative
diabetic retinopathy. AKB-9778 is also being investigated for its
potential utility in treating diabetic nephropathy and an eyedrop
formulation is in development as a potential treatment for open-angle
glaucoma. For more information, please visit www.aerpio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190226005403/en/
Source: Aerpio Pharmaceuticals, Inc.
Investor & Media:
McClellan, on behalf of Aerpio Pharmaceuticals, Inc.
Steinberg / Robert Flamm, Ph.D.